Background: With the development of monoclonal antibodies (mAbs) from the first
generation of mice to the fourth generation of human origin, the efficacy and safety in the …

In recent years, monoclonal antibodies (mAbs) have been developing rapidly and widely
used in fields of tumor, immunity, blood and other systemic diseases. Global share of mAbs …

Monoclonal antibodies (mAbs) may be used as biopharmaceuticals to treat various
diseases, ranging from oncology to inflammatory and cardiovascular affections. Trustworthy …

Monoclonal antibodies (mAbs) are an upcoming group of therapeutic compounds used to
treat various types of diseases. Currently more than 100 mAbs are in clinical development …

Most therapeutic monoclonal antibodies are designed to bind a specific antigen to elicit
pharmacological effects. Accurate quantification of a therapeutic monoclonal antibody in …

Therapeutic monoclonal antibodies (mAbs) are developed for treatment of diverse cancers
and autoimmune diseases. For expansion of mAbs approval against unapproved diseases …

Therapeutic monoclonal antibodies are one of the largest and fastest growing class of large-
molecule biotherapeutics. Accurate and reliable quantification of these biotherapeutics in …

Monoclonal antibody biotherapeutics are developed to bind to a specific target to affect the
target's biological effect. Reliable measurements of monoclonal antibodies in biological …

Monoclonal antibody (mAb) drugs currently are an important field in drug development and
playing a wide role in the treatment of autoimmune diseases and tumor. However …

Antibody drugs have become the first choice for clinical treatment of many diseases due to
their advantages of targeting, high specificity and low toxicity. However, the disposal …